CRISPR‐Cas9 significantly enhances CAR‐T outcomes by enabling precise CAR gene integration, mitigating T‐cell exhaustion through knockout of inhibitory genes (e.g., PD‐1, CTLA‐4, and LAG‐3), and improving CAR‐T survival and anti‐cancer effects by interfering with programmed cell death [115, 116, 117, 118]. Here, LAG3 is linked to cancer.